European Parliament Hearing on Pharma Legislation: A Spotlight on Childhood Cancer Needs – SIOPE
SIOP Europe, the European Society for Paediatric Oncology (SIOPE) shared a post on LinkedIn:
“European Parliament Hearing on Pharma Legislation: A Spotlight on Childhood Cancer Needs
On 10 July, the European Parliament Intergroup on Cancer and Rare Diseases held a high-level hearing in Strasbourg, bringing together policymakers, researchers, and patient advocates to discuss the future of the EU pharmaceutical legislation, now discussed in the trilogues – a final informal stage where the institutions need to converge on a definitive legislative text.
Key topics discussed during the hearing included:
- Adapting incentives to better address unmet medical needs
- Putting children with cancer at the centre of innovation and regulatory processes
- The need for balanced, patient-centred reforms that ensure sustainability, innovation, and fair access for all Europeans
As Prof. GILLES VASSAL (SIOP Europe, the European Society for Paediatric Oncology (SIOPE) and Gustave Roussy) outlined:
‘The Paediatric Medicine Regulation and the Orphan Regulation have had only limited impact on advancing the development of paediatric anticancer medicines. We call for the inclusion of a ‘first-in-child’ marketing authorisation incentive. Such a measure is expected to boost commercial interest in developing medicines specifically for paediatric cancers and other paediatric rare and ultra rare diseases.’
For the childhood cancer community, the message is clear: we need better incentives to drive innovation for children with cancer.
Want to know more?
More posts featuring SIOPE.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023